中等剂量他汀对颅内轻中度狭窄斑块的高分辨血管壁成像研究
结果显示,中等剂量他汀可使责任斑块和显著强化斑块的厚度、管腔狭窄及强化程度显著下降,且责任斑块和显著强化斑块的改善幅度更大。
要点
- 高分辨血管壁成像可显示斑块厚度、管腔狭窄及强化程度在中等剂量他汀治疗后的变化。
- 责任斑块和显著强化斑块对中等剂量他汀治疗反应更明显。
- 管腔狭窄<70%的高危颅内斑块早期他汀干预可能促进斑块稳定与回缩。
核心结论
- 与非责任斑块及轻度强化斑块相比,中等剂量他汀对管腔狭窄<70%的责任斑块和显著强化斑块具有更优的治疗效果。
研究设计与样本
- 采用高分辨血管壁成像评估斑块治疗前后特征及变化率,并对责任斑块和显著强化斑块进行亚组分析。
- 用多元线性回归分析他汀疗效与基线斑块特征之间的关系。
关键影像表现/征象
- 责任斑块最大斑块厚度(p=0.007)、斑块负荷(p=0.003)、管腔狭窄(p<0.001)和斑块强化(p<0.001)显著下降。
- 责任斑块的斑块负荷变化率(p=0.009)和管腔狭窄变化率(p=0.028)较非责任斑块下降更明显。
- 显著强化斑块最大斑块长度(p=0.044)、最大斑块厚度(p=0.036)、管腔狭窄(p=0.047)和斑块强化(p<0.001)显著下降。
- 显著强化斑块的强化程度变化率下降幅度较轻度强化斑块更显著(p=0.037)。
诊断标准与关键数值
- 管腔狭窄<70%作为入组斑块的狭窄程度标准。
- 较高斑块负荷(%,B=-0.28,S.E=0.13,p=0.036)和斑块强化程度(%,B=-0.16,S.E=0.07,p=0.015)与他汀治疗后斑块强化变化率显著相关。
临床应用与阅片要点
- 对管腔狭窄<70%的颅内动脉粥样硬化患者,高分辨血管壁成像可识别责任斑块和显著强化斑块,作为他汀治疗重点评估对象。
- 阅片时应重点关注斑块厚度、管腔狭窄程度及强化程度的变化,强化明显者可能获益更大。
- 早期他汀干预可能稳定和回缩高危颅内斑块,减少管腔狭窄,有助于卒中及短暂性脑缺血发作的二级预防。
局限性
- 回顾性研究设计可能引入选择偏倚,且未报告对照组设置。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess moderate-dose statin effects on intracranial plaques with < 70% stenosis using high-resolution vessel wall imaging (HR-VWI).
MATERIALS AND METHODS: This retrospective study enrolled patients with intracranial atherosclerosis and initiating statin therapy. HR-VWI was used to evaluate the therapeutic effects of statins on two subgroups: the culprit plaques and significantly enhanced plaques. Plaque characteristics and their change rates before and after treatment were analyzed for each subgroup. Multiple linear regression analysis was used to evaluate the relationship between the effectiveness of statin therapy and baseline plaque characteristics.
RESULTS: Fifty-two patients (age 60.4 ± 11.3 years, 40 males and 12 females) with 138 plaques were enrolled. Maximum plaque thickness (p = 0.007), plaque burden (p = 0.003), luminal stenosis (p < 0.001), and plaque enhancement (p < 0.001) were significantly reduced in culprit plaques. Culprit plaques showed greater reductions in plaque burden (p = 0.009) and luminal stenosis (p = 0.028) change rates compared to non-culprit plaques. There were significant reductions in maximum plaque length (p = 0.044), maximum plaque thickness (p = 0.036), luminal stenosis (p = 0.047), and plaque enhancement (p < 0.001) in significantly enhanced plaques. The significantly enhanced plaques also demonstrated a more pronounced decrease in enhancement change rate (p = 0.037) compared to mildly enhanced plaques. Higher plaque burden (%, B = -0.28, S.E = 0.13, p = 0.036) and plaque enhancement degree (%, B = -0.16, S.E = 0.07, p = 0.015) were positively correlated with statin treatment on plaque enhancement change rate.
CONCLUSION: Compared to non-culprit plaques and plaques with mild enhancement, moderate-dose statins demonstrate superior therapeutic efficacy for culprit plaques and significantly enhanced plaques with stenosis < 70%.
KEY POINTS: Question To assess the effects of moderate-dose statin therapy on intracranial atherosclerotic plaques with mild to moderate stenosis using high-resolution vessel wall imaging. Findings Compared to non-culprit plaques and plaques with mild enhancement, moderate-dose statins demonstrate superior therapeutic efficacy for culprit plaques and significantly enhanced plaques with stenosis < 70%. Clinical relevance Early statin intervention can stabilize and regress high-risk intracranial plaques, reduce luminal narrowing, and provide effective secondary prevention for stroke and transient ischemic attack in patients with < 70% stenosis.
引用
- Hu, Liu, Huang, et al. The effects of moderate-dose statin therapy on intracranial plaques with mild to moderate stenosis: a high-resolution MR vessel wall imaging study. Eur Radiol. 2026. PMID: 41528477. doi:10.1007/s00330-025-12247-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。